logo-loader
viewRedx Pharma Plc

Publication of Annual Report and Accounts

/**/ p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #3E639F }visited{ color: purple } .am{size:595.3pt 841.9pt;margin:72.0pt 56.65pt 72.0pt 90.0pt;}div.am{}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.bb{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.be{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}span.bg{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}span.bh{font-size:11.0pt;font-family:"Calibri","sans-serif"}p.bi{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.bj{font-size:11.0pt;font-family:"Calibri","sans-serif";color:black} span.au{font-size:11.0pt;font-family: "Calibri","sans-serif"}p.bk{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;text-autospace:none}p.bl{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}span.as{font-size:11.0pt; font-family:"Calibri","sans-serif"}table.bm{width:451.5pt; margin-left:-.75pt}td.aq{width:342.75pt;padding:.75pt .75pt .75pt .75pt}td.ap{width:105.75pt;padding:.75pt .75pt .75pt .75pt}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}span.an{font-size:11.0pt;font-family:"Calibri","sans-serif";color:blue} /**/
RNS Number : 7318L
Redx Pharma plc
28 December 2018
 

28 December 2018

 

REDX PHARMA PLC

("Redx" or "the Company")

 

Annual Report and Accounts

 

The Company announces that it will today be posting to shareholders the Annual Report and Accounts for the year ended 30 September 2018, together with the notice of the Annual General Meeting.  The Annual General Meeting will be held at 11am on 23 January 2019 at the offices of WG Partners, 85 Gresham Street, London EC2V 7NQ.

 

The Report and Accounts are also available on the Company's website, www.redxpharma.com.

 

For further information, please contact:

Redx Pharma Plc

T: +44 1625 469 920

Lisa Anson, Chief Executive Officer


Dominic Jackson, Chief Financial Officer




Cantor Fitzgerald Europe (Nominated Advisor & Joint Broker)

 T: +44 20 7894 7000

Phil Davies




WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson




FTI Consulting

T: +44 20 3727 1000

Simon Conway/Stephanie Cuthbert


 

About Redx Pharma Plc 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACSDMMZZMRDGRZM

Quick facts: Redx Pharma Plc

Price: 7

Market: AIM
Market Cap: £8.85 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Redx Pharma gets green light to increase dose in lead cancer...

Redx Pharma PLC (LON:REDX) CEO Lisa Anson spoke to Proactive London's Andrew Scott following the news they've been given the go-ahead to up the dose of its lead cancer drug. It comes after the firm successfully navigated the first part of its early-stage trial for RXC004. The asset's part...

on 20/8/19